A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma.
Clamp, Andrew R Vasey, P Soukop, M Coleman, R Halbert, G Robson, L
Clamp, Andrew R
Vasey, P
Soukop, M
Coleman, R
Halbert, G
Robson, L
Citations
Altmetric:
Abstract
Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression within 4 months of last cytotoxic therapy. All were evaluable for toxicity and 14 for response. There were no disease responses and the main toxicity was myalgia.
Description
Date
2003-10-06
Publisher
Collections
Keywords
Glandular and Epithelial Cancer
Cancer Recurrence
Ovarian Cancer
Cancer Recurrence
Ovarian Cancer
Type
Article
Citation
A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. 2003, 89 (7):1152-4 Br. J. Cancer